

TABLE OF CONTENTS

HEADS OF AGENCIES – CMDH.....	1
HEADS OF AGENCIES – PAEDIATRIC REGULATION	1
EUROPEAN MEDICINES AGENCY (EMA)	1
NOTICE TO APPLICANTS.....	7
BFARM - PHARMAKOVIGILANZ (SPECIFIC FOR GERMANY)	7
BFARM – MEDIZINPRODUKTE (SPECIFIC FOR GERMANY)	8
PEI - VIGILANZ (SPECIFIC FOR GERMANY)	8
PHARMEUROPA TEXTS FOR COMMENT.....	8

HEADS OF AGENCIES – CMDh

No updates since August 27th, 2025.

HEADS OF AGENCIES – PAEDIATRIC REGULATION

Article 45 work-sharing: [click here](#)

EUROPEAN MEDICINES AGENCY (EMA)

Date	Content	Status
08/09/2025	PSUSA: PSUSA/00002849/202411 - periodic safety update report single assessment	New
08/09/2025	Event: GIDWG Stakeholder Meeting: 1-3 October 2025	New
08/09/2025	PSUSA: PSUSA/00003162/202501 - periodic safety update report single assessment	New
05/09/2025	Medicine: Sephience	Updated
05/09/2025	EU-M4all: Lenacapavir Gilead - opinion on medicine for use outside EU	Updated
05/09/2025	Medicine: Sunosi	Updated
05/09/2025	Medicine: Wakix	Updated
05/09/2025	Medicine: Zemcelpro	Updated
05/09/2025	Medicine: Ozawade	Updated
05/09/2025	Medicine: Amsparity	Updated
05/09/2025	Medicine: Nintedanib Viatris	Updated
05/09/2025	Medicine: Hemlibra	Updated
05/09/2025	Document: Medicine shortage communication (MSC): Victoza 6 mg/mL solution for injection in pre-filled pen (liraglutide)	New

Date	Content	Status
05/09/2025	Medicine: Equilis StrepE	Updated
05/09/2025	Medicine: Enteroporc Coli AC	Updated
05/09/2025	Medicine: Emdocam	Updated
05/09/2025	Medicine: Econor	Updated
05/09/2025	Referral: Levamisole-containing medicinal products - referral	New
05/09/2025	News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 1 – 4 September 2025	New
05/09/2025	News: PRAC starts safety review of levamisole, a medicine used to treat parasitic worm infections	New
05/09/2025	Document: List of changes to combined Veterinary Dictionary for Drug Regulatory Activities (VeDDRA) list of clinical terms for reporting suspected adverse events in animal and humans to veterinary medicinal products for 2025	Updated
05/09/2025	PSUSA: PSUSA/00002669/202412 - periodic safety update report single assessment	New
04/09/2025	Medicine: Easotic	Updated
04/09/2025	Medicine: Spikevax (previously COVID-19 Vaccine Moderna)	Updated
04/09/2025	PSUSA: PSUSA/00002431/202501 - periodic safety update report single assessment	New
04/09/2025	Medicine: Draxxin	Updated
04/09/2025	PSUSA: PSUSA/00002977/202412 - periodic safety update report single assessment	New
04/09/2025	Medicine: Cortavance	Updated
04/09/2025	Medicine: Contacera	Updated
04/09/2025	PSUSA: PSUSA/00010771/202412 - periodic safety update report single assessment	New
04/09/2025	PSUSA: PSUSA/00010710/202501 - periodic safety update report single assessment	New
04/09/2025	Page: Pre-authorisation guidance under the Veterinary Medicinal Products Regulation (Regulation (EU) 2019/6)	Updated
04/09/2025	Medicine: Coliprotec F4/F18	Updated
04/09/2025	Medicine: Clynav	Updated
04/09/2025	Medicine: Clomicalm	Updated
04/09/2025	Medicine: Gazyvaro	Updated
04/09/2025	Medicine: Beyontra	Updated

Date	Content	Status
04/09/2025	Medicine: Eurartesim	Updated
04/09/2025	Medicine: Topotecan Hospira	Updated
04/09/2025	Medicine: Skyclarys	Updated
04/09/2025	Orphan: EU/3/23/2811 - orphan designation for treatment of ovarian cancer	Updated
04/09/2025	Orphan: EU/3/16/1715 - orphan designation for treatment of inherited retinal dystrophies due to defects in the RPGR gene	Updated
04/09/2025	Orphan: EU/3/23/2847 - orphan designation for treatment of CSF1R-related leukoencephalopathy	Updated
04/09/2025	Orphan: EU/3/05/297 - orphan designation for treatment of Duchenne muscular dystrophy	Updated
04/09/2025	Orphan: EU/3/22/2598 - orphan designation for treatment of giant axonal neuropathy	Updated
04/09/2025	Orphan: EU/3/07/441 - orphan designation for treatment of adrenal insufficiency	Updated
04/09/2025	Orphan: EU/3/22/2673 - orphan designation for treatment of peripheral T-cell lymphoma	Updated
04/09/2025	Orphan: EU/3/22/2742 - orphan designation for treatment of diffuse large B-cell lymphoma	Updated
04/09/2025	Orphan: EU/3/21/2410 - orphan designation for treatment of medullary thyroid carcinoma	Updated
04/09/2025	Orphan: EU/3/11/935 - orphan designation for treatment of Friedreich's ataxia	Updated
04/09/2025	Orphan: EU/3/25/3097 - orphan designation for treatment of haemophagocytic lymphohistiocytosis	New
04/09/2025	Orphan: EU/3/25/3091 - orphan designation for treatment of acute lymphoblastic leukaemia	New
04/09/2025	Orphan: EU/3/25/3096 - orphan designation for treatment of pancreatic cancer	New
04/09/2025	Orphan: EU/3/25/3089 - orphan designation for treatment of non-syndromic inherited retinal dystrophies of the rod-dominant phenotype	New
04/09/2025	Orphan: EU/3/25/3083 - orphan designation for treatment of inherited mitochondrial oxidative phosphorylation defects	New
04/09/2025	Orphan: EU/3/25/3085 - orphan designation for treatment of myelodysplastic syndromes	New
04/09/2025	Orphan: EU/3/25/3099 - orphan designation for treatment of myasthenia gravis	New

Date	Content	Status
04/09/2025	Orphan: EU/3/25/3092 - orphan designation for treatment of Charcot-Marie-Tooth disease	New
04/09/2025	Orphan: EU/3/25/3086 - orphan designation for treatment of hepatitis E	New
04/09/2025	Medicine: Triumeq	Updated
04/09/2025	Orphan: EU/3/25/3090 - orphan designation for treatment of ovarian cancer	New
04/09/2025	Orphan: EU/3/25/3084 - orphan designation for treatment of Duchenne muscular dystrophy	New
04/09/2025	Orphan: EU/3/25/3095 - orphan designation for treatment of Duchenne muscular dystrophy	New
04/09/2025	Page: Academia	Updated
04/09/2025	Orphan: EU/3/25/3098 - orphan designation for treatment of hereditary haemorrhagic telangiectasia	New
04/09/2025	Orphan: EU/3/25/3101 - orphan designation for treatment of autosomal dominant polycystic kidney disease	New
04/09/2025	Orphan: EU/3/25/3093 - orphan designation for treatment of autosomal dominant polycystic kidney disease	New
04/09/2025	Orphan: EU/3/25/3087 - orphan designation for treatment of dystrophic myotonia	New
04/09/2025	Orphan: EU/3/25/3094 - orphan designation for treatment of idiopathic inflammatory myopathy	New
04/09/2025	Orphan: EU/3/25/3100 - orphan designation for treatment of primary sclerosing cholangitis	New
04/09/2025	Orphan: EU/3/25/3088 - orphan designation for treatment of myelofibrosis	New
03/09/2025	Document: Rules for reimbursement of expenses for delegates attending meetings with effect from 17 March 2023	Updated
03/09/2025	Medicine: Clevor	Updated
03/09/2025	Medicine: Chanhold	Updated
03/09/2025	PSUSA: PSUSA/00002153/202412 - periodic safety update report single assessment	New
03/09/2025	Medicine: Rinvoq	Updated
03/09/2025	Medicine: Baycox Iron	Updated
03/09/2025	Medicine: Enzalutamide Viatriis	Updated
03/09/2025	Medicine: Lokelma	Updated
03/09/2025	Medicine: Casgevy	Updated
03/09/2025	Page: Scientific publications	Updated

Date	Content	Status
03/09/2025	Medicine: Rapiscan	Updated
03/09/2025	Medicine: Omvoh	Updated
03/09/2025	Medicine: Junod	Updated
03/09/2025	Medicine: Yeytuo	Updated
03/09/2025	News: Warning about sharp rise in illegal medicines sold in the EU	New
03/09/2025	Medicine: Poteligeo	Updated
03/09/2025	Medicine: Tepkinly	Updated
03/09/2025	Medicine: Tibsovo	Updated
03/09/2025	Medicine: Hepcludex	Updated
03/09/2025	Document: Template for submission of comments for the Veterinary Dictionary for Drug Regulatory Activities (VeDDRA) standard list for EudraVigilance Veterinary (EVVet)	Updated
03/09/2025	Medicine: Ryzneuta	Updated
02/09/2025	Medicine: Azarga	Updated
02/09/2025	Medicine: Nuvaxovid	Updated
02/09/2025	Medicine: Simbrinza	Updated
02/09/2025	Document: Appendix 1: Acceptable intakes established for N-nitrosamines	Updated
02/09/2025	Medicine: Ebilfumin	Updated
02/09/2025	Medicine: Caelyx pegylated liposomal	Updated
02/09/2025	Medicine: Syvazul BTV	Updated
02/09/2025	Medicine: Syvazul BTV 3	Updated
02/09/2025	Medicine: Daxocox	Updated
02/09/2025	Medicine: Nobivac LeuFel	Updated
02/09/2025	Medicine: Nobivac Myxo-RHD Plus	Updated
02/09/2025	Medicine: Leucogen	Updated
02/09/2025	Document: Decision of the Executive Director on rules governing the secondment of national experts to the EMA (from 1 October 2025)	New
02/09/2025	Medicine: Eravac	Updated
02/09/2025	Medicine: Startvac	Updated
02/09/2025	Medicine: Suvaxyn CSF Marker	Updated
02/09/2025	Medicine: NexGard	Updated
02/09/2025	Medicine: Nexgard Spectra	Updated

Date	Content	Status
02/09/2025	Medicine: Fluralaner Intervet	Updated
02/09/2025	Medicine: Innovax-ND-IBD-ILT	Updated
02/09/2025	Medicine: Blenrep	Updated
02/09/2025	Document: EU Implementation Guide (IG) on veterinary medicines product data in the Union Product Database - Chapter 6: Examples for submission of legacy data (obsolete)	Updated
02/09/2025	Document: EU Implementation Guide (IG) on veterinary medicines product data in the Union Product Database - Chapter 4: Process and format for the submission of legacy data on veterinary medicinal products (obsolete)	Updated
02/09/2025	Medicine: Nobilis Multiriva Gm+REOm	Updated
02/09/2025	Medicine: Nobilis Multiriva IBm+ND	Updated
02/09/2025	Medicine: Pluvicto	Updated
01/09/2025	Document: Agenda of the PRAC meeting 1-4 September 2025	New
01/09/2025	Medicine: Bravecto CombiUNO	Updated
01/09/2025	Medicine: Zenrelia	Updated
01/09/2025	Medicine: Numelvi	Updated
01/09/2025	Medicine: Jcovden (previously COVID-19 Vaccine Janssen)	Updated
01/09/2025	Event: Clinical Trials Information System (CTIS): Walk-in clinic September 2025	New
01/09/2025	Event: Committee for Advanced Therapies (CAT) workshop on gene editing	Updated
01/09/2025	News: EMA and WHO mark ten years of collaboration to advance global access to medicines	New
01/09/2025	Page: World Health Organization (WHO)	Updated
01/09/2025	Document: Infosheet: European Medicines Agency - World Health Organization collaboration and partnership	New
01/09/2025	Page: Transfer of data on suspected adverse reactions to WHO	New
01/09/2025	Document: Applications for new human medicines under evaluation: September 2025	New
01/09/2025	Document: Veterinary Dictionary for Drug Regulatory Activities (VeDDRA) dataload friendly file including deprecated terms	Updated
01/09/2025	Page: Industry Standing Group meetings	Updated
01/09/2025	Event: 14th Industry Standing Group (ISG) meeting	New
01/09/2025	Page: Administration and Corporate Management	Updated

Date	Content	Status
01/09/2025	Event: European Platform for Regulatory Science Research meeting September 2025	New
01/09/2025	Referral: Finasteride- and dutasteride-containing medicinal products - referral	Updated
01/09/2025	Document: Organisation chart: Administration and Corporate Management	Updated

NOTICE TO APPLICANTS

3 September 2025

[Stakeholders' Consultation on EudraLex Volume 4 - Good Manufacturing Practice Guidelines: Chapter 1](#)

BFARM - PHARMAKOVIGILANZ (SPECIFIC FOR GERMANY)

Date	Title
08.09.2025	Rote-Hand-Brief zu Clozapin: Überarbeitete Empfehlungen zur routinemäßigen Blutbildkontrolle im Hinblick auf das Risiko einer Agranulozytose Wirkstoff: Clozapin Die Zulassungsinhaber von clozapinhaltigen Arzneimitteln informieren über die überarbeiteten Empfehlungen zur routinemäßigen Blutbildkontrolle.
08.09.2025	Umsetzung des einstimmigen Beschlusses der Koordinierungsgruppe vom 24.07.2025 betreffend die Zulassungen für Humanarzneimittel mit dem Wirkstoff Domperidon Das BfArM veröffentlicht den Umsetzungsbescheid für den Wirkstoff Domperidon infolge des Europäischen PSUR Single Assessment Verfahrens nach Artikel 107d) bis g) der Richtlinie 2001/83/EG.
08.09.2025	Umsetzung des einstimmigen Beschlusses der Koordinierungsgruppe vom 24.07.2025 betreffend die Zulassungen für Humanarzneimittel mit dem Wirkstoff Nicotin Das BfArM veröffentlicht den Umsetzungsbescheid für den Wirkstoff Nicotin infolge des Europäischen PSUR Single Assessment Verfahrens nach Artikel 107d) bis g) der Richtlinie 2001/83/EG.
05.09.2025	Informationen zu Rote-Hand-Briefen und Informationsbriefen Das Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) veröffentlicht neue Hinweise zu anstehenden Rote-Hand-Briefen und Informationsbriefen.

Date	Title
05.09.2025	Levamisol: Überprüfung des Risikos für eine Leukoenzephalopathie Wirkstoff: Levamisol Die Europäische Arzneimittel-Agentur (EMA) beginnt mit der Sicherheitsüberprüfung von levamisolhaltigen Arzneimitteln zur Behandlung von parasitären Wurminfektionen.
05.09.2025	Pharmacovigilance Risk Assessment Committee (PRAC) Das Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) veröffentlicht die neuen Signale, die im Rahmen der PRAC-Sitzung vom 01.09.-04.09.2025 behandelt wurden.
02.09.2025	Umsetzung des Durchführungsbeschlusses der Europäischen Kommission vom 21.08.2025 zum PSUR Single Assessment betreffend die Zulassungen für Humanarzneimittel mit dem Wirkstoff (E)-Stiripentol Das BfArM veröffentlicht den Umsetzungsbescheid für den Wirkstoff (E)-Stiripentol infolge des Europäischen PSUR Single Assessment Verfahrens nach Artikel 107d) bis g) der Richtlinie 2001/83/EG.
01.09.2025	Umsetzung des einstimmigen Beschlusses der Koordinierungsgruppe vom 19.06.2025 betreffend die Zulassungen für Humanarzneimittel mit dem Wirkstoff Isoniazid Das BfArM veröffentlicht den Umsetzungsbescheid für den Wirkstoff Isoniazid infolge des Europäischen PSUR Single Assessment Verfahrens nach Artikel 107d) bis g) der Richtlinie 2001/83/EG.

BFARM – MEDIZINPRODUKTE (SPECIFIC FOR GERMANY)

No updates since August 26th, 2025.

PEI - VIGILANZ (SPECIFIC FOR GERMANY)

No updates since May 22nd, 2025.

PHARMEUROPA TEXTS FOR COMMENT

Information on Pharmeduropa updates will be presented quarterly.

Trotz regelmäßiger Aktualisierung und sorgfältiger Überwachung der Veröffentlichungen können wir keine Haftung oder Garantie für die Aktualität, Richtigkeit und Vollständigkeit der hier bereitgestellten Informationen übernehmen. Dieser Newsletter enthält Links zu anderen Websites. Trotz sorgfältiger inhaltlicher Kontrolle übernehmen wir keine Haftung für die Inhalte externer Links. Für den Inhalt der verlinkten Seiten sind ausschließlich deren Betreiber verantwortlich.

Despite regular updating and careful monitoring of the publications, we cannot take any responsibility or guarantee for the topicality, correctness and completeness of the information provided here. This Newsletter contains links to other websites. Despite careful control of the content we would like to point out that we are not liable for the contents of external web links. The editors of the respective websites are fully responsible for their contents.